NIOX Group (LON:NIOX) Insider Jonathan Emms Sells 325,273 Shares

NIOX Group Plc (LON:NIOX) insider Jonathan Emms sold 325,273 shares of the stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of GBX 56, for a total transaction of £182,152.88.

NIOX Group Trading Up 1.4%

Shares of LON:NIOX opened at GBX 57.40 on Friday. NIOX Group Plc has a 52 week low of GBX 53.84 and a 52 week high of GBX 77.60. The company’s 50 day moving average is GBX 60.68 and its two-hundred day moving average is GBX 66.40. The company has a current ratio of 3.81, a quick ratio of 1.94 and a debt-to-equity ratio of 1.36. The company has a market cap of £239.97 million, a PE ratio of 35.00 and a beta of 0.92.

NIOX Group (LON:NIOX) last announced its quarterly earnings data on Tuesday, March 24th. The company reported GBX 4.03 EPS for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. Equities analysts predict that NIOX Group Plc will post 1.1658256 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Deutsche Bank Aktiengesellschaft dropped their target price on shares of NIOX Group from GBX 90 to GBX 86 and set a “buy” rating on the stock in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, NIOX Group presently has an average rating of “Buy” and an average target price of GBX 86.

NIOX Group Company Profile

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.